MRNA-based precision targeting of neoantigens and tumor-associated antigens in malignant brain tumors.

ABSTRACT:

Background

Despite advancements in the successful use of immunotherapy in treating a variety of solid tumors, applications in treating brain tumors have lagged considerably. This is due, at least in part, to the lack of well-characterized antigens expressed within brain tumors that can mediate tumor rejection; the low mutational burden of these tumors that limits the abundance of targetable neoantigens; and the immunologically "cold" tumor microenvironment that hampers the generation of sustained and productive immunologic responses. The field of mRNA-based therapeutics has experienced a boon following the universal approval of COVID-19 mRNA vaccines. mRNA-based immunotherapeutics have also garnered widespread interest for their potential to revolutionize cancer treatment. In this

SUBMITTER: Trivedi V 

PROVIDER: S-EPMC10809449 | biostudies-literature | 2024 Jan

REPOSITORIES: biostudies-literature